SENTINEL NODE BIOPSY WITH MAGTRACE® IN A HER2-POSITIVE PATIENT DIAGNOSED DURING PREGNANCY WITH COMPLETE CLINICAL RESPONSE TO NEOADJUVANT TREATMENT

Autores

  • Jaime Letzkus University of Chile, Medical Faculty, Hospital San Borja Arriarán – Santiago, Chile.
  • Jorge Gamboa Galté University of Chile, Medical Faculty, Hospital San Borja Arriarán – Santiago, Chile.
  • María José del Río University of Chile, Medical Faculty, Hospital San Borja Arriarán – Santiago, Chile.
  • Alejandro Belmar University of Chile, Medical Faculty, Hospital San Borja Arriarán – Santiago, Chile.
  • José Manuel Lagos Bononato University of Chile, Medical Faculty, Hospital San Borja Arriarán – Santiago, Chile.
  • Andrea Sepúlveda University of Chile, Medical Faculty, Hospital San Borja Arriarán – Santiago, Chile.

DOI:

https://doi.org/10.29289/259453942022V32S2081

Palavras-chave:

Breast cancer, Neoadjuvant treatment, Sentinel node, Pregnancy

Resumo

During the past decades, there has been significant progress in breast cancer diagnosis and treatment, which has led to
improvement in overall and breast cancer-specific survival. It has also enabled the possibility of de-escalating the extent
of surgeries. There is growing evidence that supports sentinel lymph node biopsy (SLNB) after neoadjuvant treatment,
even in cases with positive lymph nodes at diagnosis. One of the key goals is the achievement of low false-negative rates
for SLMB detection. Technetium-99 (Tc99) is considered the gold standard tracer worldwide. Nonetheless, access to a
nuclear medicine department, the timing of Tc99 injection, operating room schedules, and administrative limitations
can cause increased overall costs of care and patient discomfort. There is compelling evidence that supports the use of
new tracers; one of these is the superparamagnetic iron oxide (SPIO, Magtrace®). The SPIO allows the detection of the
sentinel node marking hot spots and has the advantage of dyeing the nodes with a brownish color. We present a novel
experience with this tracer in a Chilean public hospital. A 33-year-old patient was diagnosed with right breast cancer
during pregnancy (21 weeks). The core biopsy revealed an invasive ductal carcinoma HER2-positive, cT2N0M0 (25 mm).
The patient completed neoadjuvant chemotherapy, and pregnancy interruption was scheduled at 37 weeks by cesarean
section. Trastuzumab (TTZ) was initiated right after delivery and breast conservation surgery with SLNB using SPIO, and
blue dye was performed thereafter. Intraoperative biopsy revealed three negative nodes, concordant with the hot spots and
dyeing seen in surgery. This case shows the efficacy of neoadjuvant treatment and TTZ in HER2-positive patients with a
high rate of complete clinical response. In our opinion, this new tracer is an excellent and affordable alternative to Tc99
and could avoid the use of blue dye.

Downloads

Não há dados estatísticos.

Downloads

Publicado

2026-04-01

Como Citar

Letzkus, J., Galté, J. G., Río, M. J. del, Belmar, A., Bononato, J. M. L., & Sepúlveda, A. (2026). SENTINEL NODE BIOPSY WITH MAGTRACE® IN A HER2-POSITIVE PATIENT DIAGNOSED DURING PREGNANCY WITH COMPLETE CLINICAL RESPONSE TO NEOADJUVANT TREATMENT. Mastology, 32(suppl.2). https://doi.org/10.29289/259453942022V32S2081

Edição

Seção

E-poster